Celularity Inc (CELU) stock

CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 20, 2026Score 7/30

$0.68−0.07 (-8.81%)

Close on Nov 12, 2026Market cap $22.22MP/E –Yield –

Celularity EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Celularity has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CELU.

Revenue growth-58.1% · median 73.5%

Gross margin19.2% · median 88.0%

Operating margin-264.3% · median -93.1%

Net margin-245.7% · median -133.9%

Advertisement
300 × 250

See a number that looks wrong?